Intas Pharmaceuticals, a mid-size generic firm from India, will conduct late phase clinical studies of Amarillo Biosciences' oral interferon-alpha lozenges in India.

World's top drug maker is now hunting for Indian partners for possible alliances and buyouts to boost its earnings which is suffering form nagative impacts due to patent expiration of some of its block-buster drugs, reports said.